Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 3/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740707 | 1.00 | PDE4B (0.36) | PDE4BFPR2FFAR4RARBSPHK1 | |
| SCHEMBL12740711 | 0.94 | RARB (0.35) | FFAR4RARBSPHK1ALOX5APFEN1 | |
| SCHEMBL12735998 | 0.94 | RARB (0.35) | FFAR4RARBSPHK1ALOX5APFEN1 | |
| SCHEMBL12735981 | 0.89 | FPR2 (0.38) | PDE4BFPR2ALOX5APFEN1 | |
| SCHEMBL12740706 | 0.89 | FPR2 (0.38) | PDE4BFPR2ALOX5APFEN1 | |
| SCHEMBL12740704 | 0.89 | FFAR4 (0.34) | FFAR4RARBSPHK1ALOX5APFEN1 | |
| SCHEMBL12735995 | 0.89 | FFAR4 (0.34) | FFAR4RARBSPHK1ALOX5APFEN1 | |
| SCHEMBL12740747 | 0.88 | FFAR1 (0.39) | FFAR4RARBPPARA | |
| SCHEMBL12740780 | 0.88 | HTR2A (0.38) | FFAR4RARBPPARACASP3SENP8 | |
| SCHEMBL12736177 | 0.88 | HTR2A (0.38) | PDE4BFFAR4RARBCASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | PDE4B 2984/4885FPR2 589/4885FFAR4 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.